Lilly launches oral GLP-1 Foundayo at $149 a month as early prescriptions trail Wegovy pill

Eli Lilly has begun selling Foundayo (orforglipron), a once-daily oral GLP-1 pill, to patients in the United States at a self-pay price of $149 a month for people paying cash ^[2]. Reuters counted about 1,390 U.S. prescriptions for the new pill in its launch week ^[1], a start that trailed Novo Nordisk's competing oral Wegovy (semaglutide) pill ^[1].

A comparable launch-week prescription total for the Wegovy pill has not been disclosed, so how far behind Foundayo started is not yet known. One pharmaceutical industry report described the oral launch as disappointing ^[2].

Foundayo is Lilly's pill entry into a market the company has so far dominated with injectables. Its GLP-1 business still rests on tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity and weight management ^[2]. Those injectable products continued to grow even as the new pill's early numbers came in below expectations ^[2].

The $149 monthly figure applies to people paying out of pocket ^[2]. What insurers, employers or pharmacy benefit managers will charge for Foundayo has not been disclosed, and it is not known how many of the launch-week prescriptions were cash purchases versus covered ones ^[2].

Foundayo is orforglipron, not semaglutide. The oral Wegovy pill, Ozempic and Rybelsus are semaglutide products, and Mounjaro and Zepbound are tirzepatide. The medications are not interchangeable, and switching between them is a decision for a prescriber.

Why it matters for patients

• Adults who prefer a pill to an injection now have an oral GLP-1 option from a second manufacturer, with a published cash price of $149 a month ^[2]. That number gives people who pay out of pocket a figure to compare with other cash-pay options, though it says nothing about what a given person would actually pay.
• Insurance coverage for Foundayo has not been announced ^[2]. Whether it lands on formularies, and at what patient cost, is unresolved.
• A single week of prescription counts is an early signal about how quickly prescribers and patients adopt a new drug. It is not evidence about how well the drug works, how well people tolerate it, or how many stay on it. Launch-week refill and persistence data have not been reported ^[1].
• The comparison with Novo Nordisk's oral Wegovy is incomplete without that product's launch-week total, which has not been disclosed ^[1].
• Foundayo's arrival does not change Lilly's reliance on injectable tirzepatide, which remains the larger part of its GLP-1 business ^[2].

What happens next

No date has been announced for the next public look at Foundayo prescription volumes, and neither company has said when it will report further launch figures ^[1][2]. Coverage decisions by insurers and pharmacy benefit managers, and any change to the $149 self-pay price, have not been disclosed ^[2]. Long-term data on how many patients stay on the pill have not been reported ^[1].